Sökning: "Thrombin-inhibitors"

Visar resultat 1 - 5 av 12 avhandlingar innehållade ordet Thrombin-inhibitors.

  1. 1. Experimental studies on thrombosis and thrombolysis : With special reference to importance of lys-plasminogen, active site thrombin inhibitors and stable fish oil

    Författare :Liying Chen; Uppsala universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Surgery; Thrombolysis; thrombosis; recombinant tissue-type plasminogen activator; lys- and glu-plasminogen; aspirin; thrombin inhibitors; platelets; superoxide dismutase; stable fish oil; Kirurgi; Surgery; Kirurgi; rättsmedicin; Forensic Medicine;

    Sammanfattning : Dissolution and prevention of thrombus in the atherosclerotic coronary artery have become an important part of treatment therapy of acute myocardial infarction. However, the currently most effective thrombolytic agent, recombinant tissue-type plasminogen activator (rt-PA), only elicits 80% recanalization of thrombotically occluded coronary arteries and early occlusion occurs in about 40% of successfullyrecanalized vessels. LÄS MER

  2. 2. Synthesis of a targeted library and thrombin inhibitors using organometallic chemistry

    Författare :Fredrik Thorstensson; Linköpings universitet; []

    Sammanfattning : The use of organometallic chemistry in the pursuit of novel scaffolds is outline d. A 4-phenyl- 2-carboxy-piperazine targeted combinatorial chemistry library has been synthesized aimed at the early lead discovery phase. LÄS MER

  3. 3. The effect of thrombin inhibitors on coagulation activity and generation of activated protein C

    Författare :Rikard Linder; Karolinska Institutet; Karolinska Institutet; []

    Sammanfattning : The direct thrombin inhibitor inogatran was, in the TRIM trial (n=1209), compared with unfractionated heparin (UFH) concerning the effect on cardiovascular end-points in unstable coronary artery disease. The results in TRIM demonstrated a trend towards a benefit for UFH during the treatment phase, which was reduced after drug withdrawal. LÄS MER

  4. 4. Direct Thrombin Inhibitors in Treatment and Prevention of Venous Thromboembolism: Dose – Concentration – Response Relationships

    Författare :Marie Cullberg; Mats O. Karlsson; Ulf G. Eriksson; Nick H.G. Holford; Uppsala universitet; []
    Nyckelord :Pharmaceutical biosciences; Ximelagatran; pharmacokinetic; pharmacodynamic; activated partial thromboplastin time; utility function; dosing strategy; venous thromboembolism; NONMEM; Farmaceutisk biovetenskap;

    Sammanfattning : For prevention and treatment of thrombotic diseases with an anticoagulant drug it is important that an adequate dose is given to avoid occurrence or recurrence of thrombosis, without increasing the risk of bleeding and other adverse events to unacceptable levels. The aim of this thesis was to develop mathematical models that describe the dose-concentration (pharmacokinetic) and concentration-response (pharmacodynamic) relationships of direct thrombin inhibitors, in order to estimate optimal dosages for treatment and long-term secondary prevention of venous thromboembolism (VTE). LÄS MER

  5. 5. In vivo Pharmacokinetics of Two New Thrombin Inhibitor Prodrugs : Emphasis on Intestinal and Hepatobiliary Disposition and the Influence of Interacting Drugs

    Författare :Elin Matsson; Hans Lennernäs; Lars Knutson; Ulf Eriksson; Kim Brouwer; Uppsala universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Direct thrombin inhibitors; prodrugs; ximelagatran; AZD0837; erythromycin; ketoconazole; drug-drug interactions; hepatobiliary transport; biliary clearance; ATP-binding cassette; ABC transporters; solute carriers; SLC transporters; CYP3A4; Biopharmacy; Biofarmaci; Biopharmaceutics; Biofarmaci;

    Sammanfattning : Biliary excretion is an important elimination route for many drugs and metabolites. For such compounds, it is important to know the extent of excretion and drug exposure in the bile, e.g., for the risk assessment of drug interactions, liver toxicity and the effects of genetic variants. LÄS MER